Human VEGF165 Antibody

Catalog # Availability Size / Price Qty
AB-293-NA
Cell Proliferation Induced by VEGF165 and Neutralization by Human VEGF Antibody.
3 Images
Product Details
Citations (7)
FAQs
Supplemental Products
Reviews

Human VEGF165 Antibody Summary

Species Reactivity
Human
Specificity
Detects human VEGF165 and human VEGF121 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse VEGF and recombinant rat VEGF is observed.
Source
Polyclonal Goat IgG
Purification
Protein A or G purified
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGF165
Ala27-Arg191
Accession # AAV38412
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
Recombinant Human VEGF165 (Catalog # 293-VE)
Immunohistochemistry
5-15 µg/mL
See below
Neutralization
Measured by its ability to neutralize VEGF165-induced proliferation in HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci USA 87:1323. The Neutralization Dose (ND50) is typically 0.6‑3.0 µg/mL in the presence of 10 ng/mL Recombinant Human VEGF165.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Neutralization Cell Proliferation Induced by VEGF165 and Neutralization by Human VEGF Antibody. View Larger

Cell Proliferation Induced by VEGF165 and Neutralization by Human VEGF Antibody. Recombinant Human VEGF165 (Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human VEGF165 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA). The ND50 is typically 0.6-3.0 µg/mL.

Immunohistochemistry VEGF165 in Human Breast Cancer Tissue. View Larger

VEGF165 in Human Breast Cancer Tissue. VEGF165 was detected in immersion fixed frozen sections of human breast cancer tissue using 5 µg/mL Human VEGF165 Polyclonal Antibody (Catalog # AB‑293‑NA) overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Immunohistochemistry VEGF in Human Breast Cancer Tissue. View Larger

VEGF in Human Breast Cancer Tissue. VEGF was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Human VEGF 165 Polyclonal Antibody (Catalog # AB-293-NA) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 1 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1‑3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189 (3, 4). Isoforms other than VEGF121 contain basic heparin-binding regions and are not freely diffusible (4). Human VEGF165 shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF, respectively. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). VEGF165 binds the semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2 (5). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 4). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (3). Pathologically, it is involved in tumor angiogenesis and vascular leakage (6, 7). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (8). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M and TNF-alpha (3, 4, 9).

References
  1. Leung, D.W. et al. (1989) Science 246:1306. 
  2. Keck, P.J. et al. (1989) Science 246:1309. 
  3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777. 
  4. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
  5. Pan, Q. et al. (2007) J. Biol. Chem. 282:24049.
  6. Weis, S.M. and D.A. Cheresh (2005) Nature 437:497.
  7. Thurston, G. (2002) J. Anat. 200:575.
  8. Carvalho, J.F. et al. (2007) J. Clin. Immunol. 27:246.
  9. Angelo, L.S. and R. Kurzrock (2007) Clin. Cancer Res. 13:2825.
Long Name
Vascular Endothelial Growth Factor
Entrez Gene IDs
7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
Alternate Names
MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Product Datasheets

Citations for Human VEGF165 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

7 Citations: Showing 1 - 7
Filter your results:

Filter by:

  1. High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy
    Authors: AM Kivelä, J Huusko, E Gurzeler, A Laine, MH Dijkstra, G Dragneva, CB Andersen, SK Moestrup, S Ylä-Herttu
    Sci Rep, 2017;7(1):386.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  2. Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma.
    Authors: Kondo S, Mukudai Y, Soga D, Nishida T, Takigawa M, Shirota T
    Anticancer Res, 2014;34(2):671-7.
    Species: Human
    Sample Types: Cell Lysates
    Applications: WB
  3. Extensive podocyte loss triggers a rapid parietal epithelial cell response.
    Authors: Hakroush S, Cebulla A, Schaldecker T, Behr D, Mundel P, Weins A
    J Am Soc Nephrol, 2014;25(5):927-38.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  4. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
    Authors: Lewin J, Khamly K, Young R, Mitchell C, Hicks R, Toner G, Ngan S, Chander S, Powell G, Herschtal A, Te Marvelde L, Desai J, Choong P, Stacker S, Achen M, Ferris N, Fox S, Slavin J, Thomas D
    Br J Cancer, 2014;111(12):2254-61.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC
  5. Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.
    Authors: Uniewicz KA, Cross MJ, Fernig DG
    J. Biol. Chem., 2011;286(1):12-23.
    Species: Human
    Sample Types: Buffer
    Applications: Other: See notes
  6. Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus.
    Authors: Nicoletti JN, Shah SK, McCloskey DP, Goodman JH, Elkady A, Atassi H, Hylton D, Rudge JS, Scharfman HE, Croll SD
    Neuroscience, 2007;151(1):232-41.
    Species: Rat
    Sample Types: Cell Culture Supernates
    Applications: ELISA Development
  7. Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation.
    Authors: Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM
    J. Oral Pathol. Med., 2001;30(8):449-57.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC Paraffin-embedded

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Cell and Tissue Staining Kits

Immunohistochemistry Reagents

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human VEGF165 Antibody

There are currently no reviews for this product. Be the first to review Human VEGF165 Antibody and earn rewards!

Have you used Human VEGF165 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review